Recent News

• 04.15.2025 - Cue Biopharma Business Update Call
• 04.15.2025 - Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering
• 04.15.2025 - Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering
• 04.14.2025 - Cue Biopharma Announces Proposed Public Offering
• 04.14.2025 - Cue Biopharma Announces Proposed Public Offering
• 04.14.2025 - Cue Biopharma to Host Business Update Call and Webcast
• 04.14.2025 - Cue Biopharma to Host Business Update Call and Webcast
• 04.14.2025 - Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases
• 04.14.2025 - Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases
• 03.31.2025 - Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Recent Filings

• 04.14.2025 - PRE 14A Other preliminary proxy statements
• 04.14.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 04.14.2025 - 8-K Current report
• 03.31.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.31.2025 - 8-K Current report
• 03.31.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.31.2025 - EX-99.1 EX-99.1
• 03.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.25.2025 - 4 Statement of changes in beneficial ownership of securities